Gustavo Lopez‐Lopez
Gustavo Lopez‐Lopez has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso Díaz
Institute of Physiology, Benemerita Universidad Autonoma de Puebla, Puebla, Mexico
2 shared publications - Gonzalo Flores
Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla (BUAP), Puebla 72570, Mexico
2 shared publications - Jorge Guevara
Department of Biochemistry, Faculty of Medicine National Autonomous University of Mexico Mexico City Mexico
2 shared publications - Rubén Antonio Vázquez-Roque
Institute of Physiology, Benemerita Universidad Autonoma de Puebla (BUAP), Puebla 72590, Mexico
2 shared publications - Samuel Treviño
Laboratory of Metabolomic and Chronic Degenerative Diseases, Physiology Institute, Meritorious Autonomous University of Puebla, Puebla, Mexico
2 shared publications - Abimael González-Hernández
Universidad Nacional Autónoma de México
1 shared publication
Latest Publications
- Open Access
- 7 October 2025
- Published by Wiley in Drug Development Research
- Vol. 86 (7) , e70177
Cardiovascular Safety of VIAN‐c4551, an Antiangiogenic Peptide Derived From Vasoinhibin
Vasoinhibin is a potent antiangiogenic protein that blocks the activation of endothelial nitric oxide synthase (eNOS) in response to vascular endothelial growth factor, bradykinin, and acetylcholine (ACh). In this regard, VIAN‐c4551, a new synthetic vasoinhibin analog, has therapeutic potential for targeting angiogenesis in oncology and ophthalmology. Given that cardiovascular actions are common complications of antiangiogenic drugs and eNOS inhibitors, this multidisciplinary study investigated the cardiovascular safety of VIAN‐c4551. Administered acutely, VIAN‐c4551 inhibited ACh‐induced eNOS phosphorylation/activation in cultured endothelial cells and in lung tissue treated in vivo, as well as the ACh‐induced relaxation of rat aortic segments. However, daily intravenous (i.v.) injections of VIAN‐c4551 (1 or 3 mg kg −1 ) for 5 days failed to significantly modify the vasodepressor responses to ACh and the baseline values of blood pressure in anesthetized rats (intact, vagotomized, or pithed). Furthermore, daily i.v. injections of 1 mg kg −1 VIAN‐c4551 (for 5 days) did not alter: (i) blood pressure or heart rate values in awake rats; (ii) cardiac autonomic and histological outcomes in anesthetized animals; or (iii) inflammatory (tumor necrosis factor‐α [TNF‐α] and interleukin‐6 [IL‐6]) and apoptotic (caspase‐3) markers. Although VIAN‐c4551 inhibited ACh‐induced eNOS activation in vitro and in vivo and vasorelaxation in ex vivo assays, in vivo experiments consistently showed no significant cardiovascular effects produced by this synthetic peptide. Thus, VIAN‐c4551 appears to be cardiovascularly safe for targeting angiogenesis‐related diseases.
- 7 October 2025
- Published by Wiley in Drug Development Research
- Vol. 86 (7) , e70177
Open AccessCardiovascular Safety of VIAN‐c4551, an Antiangiogenic Peptide Derived From Vasoinhibin
Vasoinhibin is a potent antiangiogenic protein that blocks the activation of endothelial nitric oxide synthase (eNOS) in response to vascular endothelial growth factor, bradykinin, and acetylcholine (ACh). In this regard, VIAN‐c4551, a new synthetic vasoinhibin analog, has therapeutic potential for targeting angiogenesis in oncology and ophthalmology. Given that cardiovascular actions are common complications of antiangiogenic drugs and eNOS inhibitors, this multidisciplinary study investigated the cardiovascular safety of VIAN‐c4551. Administered acutely, VIAN‐c4551 inhibited ACh‐induced eNOS phosphorylation/activation in cultured endothelial cells and in lung tissue treated in vivo, as well as the ACh‐induced relaxation of rat aortic segments. However, daily intravenous (i.v.) injections of VIAN‐c4551 (1 or 3 mg kg −1 ) for 5 days failed to significantly modify the vasodepressor responses to ACh and the baseline values of blood pressure in anesthetized rats (intact, vagotomized, or pithed). Furthermore, daily i.v. injections of 1 mg kg −1 VIAN‐c4551 (for 5 days) did not alter: (i) blood pressure or heart rate values in awake rats; (ii) cardiac autonomic and histological outcomes in anesthetized animals; or (iii) inflammatory (tumor necrosis factor‐α [TNF‐α] and interleukin‐6 [IL‐6]) and apoptotic (caspase‐3) markers. Although VIAN‐c4551 inhibited ACh‐induced eNOS activation in vitro and in vivo and vasorelaxation in ex vivo assays, in vivo experiments consistently showed no significant cardiovascular effects produced by this synthetic peptide. Thus, VIAN‐c4551 appears to be cardiovascularly safe for targeting angiogenesis‐related diseases.
- Open Access
- 8 October 2024
- Published by Centro Latinoamericano de Investigación y Ciencias in Revista Científica de Salud y Desarrollo Humano
- Vol. 5 (4) , 1849-1866
Percepción del riesgo laboral en el personal de enfermería, que maneja medicamentos antineoplásicos
La percepción del riesgo laboral de cada persona es una parte importante para entender el comportamiento ante la presencia del riesgo. Es Importante hacer énfasis y conocer la forma en que piensan los trabajadores para predecir la respuesta que tendrán frente al riesgo. Objetivo. Conocer la percepción del riesgo laboral del personal de Enfermería, que maneja medicamentos antineoplásicos. Metodología. Estudio observacional, transversal, con información proleptiva, unicentrico y descriptivo. Bajo criterios de selección y consentimiento informado, se aplicó cuestionario a un total de 103 enfermeras que manejan directamente los medicamentos antineoplásicos, en el “Centro Estatal de Cancerología en Xalapa, Veracruz. Para la recolección de información, se procedió a la aplicación del cuestionario de Evaluación Dimensional del Riesgo Percibido por el Trabajador (EDRP-T) desarrollado por Portell-Vidal y Solé-Gómez en el año 2003. Es un instrumento que ha sido validado por el Instituto Nacional de Seguridad e Higiene en el Trabajo en la NTP 578. Resultados y conclusión. Se obtuvo la estimación de la magnitud del riesgo percibido; 23% de los trabajadores encuestados valoro como riesgo alto y 57% valoró como un riesgo muy alto el uso de antineoplásicos. Se considera una percepción adecuada del riesgo, los trabajadores no subestiman el peligro asociado al manejo de dichos medicamentos., por lo que el uso de EPP debe ser usado adecuadamente.
- 8 October 2024
- Published by Centro Latinoamericano de Investigación y Ciencias in Revista Científica de Salud y Desarrollo Humano
- Vol. 5 (4) , 1849-1866
Open AccessPercepción del riesgo laboral en el personal de enfermería, que maneja medicamentos antineoplásicos
La percepción del riesgo laboral de cada persona es una parte importante para entender el comportamiento ante la presencia del riesgo. Es Importante hacer énfasis y conocer la forma en que piensan los trabajadores para predecir la respuesta que tendrán frente al riesgo. Objetivo. Conocer la percepción del riesgo laboral del personal de Enfermería, que maneja medicamentos antineoplásicos. Metodología. Estudio observacional, transversal, con información proleptiva, unicentrico y descriptivo. Bajo criterios de selección y consentimiento informado, se aplicó cuestionario a un total de 103 enfermeras que manejan directamente los medicamentos antineoplásicos, en el “Centro Estatal de Cancerología en Xalapa, Veracruz. Para la recolección de información, se procedió a la aplicación del cuestionario de Evaluación Dimensional del Riesgo Percibido por el Trabajador (EDRP-T) desarrollado por Portell-Vidal y Solé-Gómez en el año 2003. Es un instrumento que ha sido validado por el Instituto Nacional de Seguridad e Higiene en el Trabajo en la NTP 578. Resultados y conclusión. Se obtuvo la estimación de la magnitud del riesgo percibido; 23% de los trabajadores encuestados valoro como riesgo alto y 57% valoró como un riesgo muy alto el uso de antineoplásicos. Se considera una percepción adecuada del riesgo, los trabajadores no subestiman el peligro asociado al manejo de dichos medicamentos., por lo que el uso de EPP debe ser usado adecuadamente.
Chronic resveratrol administration reduces oxidative stress and brain cell loss and improves memory of recognition in old rats
The cognitive functions of people over 60 years of age have been diminished, due to the structural and functional changes that the brain has during aging. The most evident changes are at the behavioral and cognitive level, with decreased learning capacity, recognition memory, and motor incoordination. The use of exogenous antioxidants has been implemented as a potential pharmacological option to delay the onset of brain aging by attenuating oxidative stress and neurodegeneration. Resveratrol (RSVL) is a polyphenol present in various foods, such as red fruits, and drinks, such as red wine. This compound has shown great antioxidant capacity due to its chemical structure. In this study, we evaluated the effect of chronic RSVL treatment on oxidative stress and cell loss in the prefrontal cortex, hippocampus, and cerebellum of 20‐month‐old rats, as well as its impact on recognition memory and motor behavior. Rats treated with RSVL showed an improvement in locomotor activity and in short‐ and long‐term recognition memory. Likewise, the concentration of reactive oxygen species and lipid peroxidation decreased significantly in the group with RSVL, coupled with an improvement in the activity of the antioxidant system. Finally, with the help of hematoxylin and eosin staining, it was shown that chronic treatment with RSVL prevented cell loss in the brain regions studied. Our results demonstrate the antioxidant and neuroprotective capacity of RSVL when administered chronically. This strengthens the proposal that RSVL could be an important pharmacological option to reduce the incidence of neurodegenerative diseases that affect older adults.
Chronic resveratrol administration reduces oxidative stress and brain cell loss and improves memory of recognition in old rats
The cognitive functions of people over 60 years of age have been diminished, due to the structural and functional changes that the brain has during aging. The most evident changes are at the behavioral and cognitive level, with decreased learning capacity, recognition memory, and motor incoordination. The use of exogenous antioxidants has been implemented as a potential pharmacological option to delay the onset of brain aging by attenuating oxidative stress and neurodegeneration. Resveratrol (RSVL) is a polyphenol present in various foods, such as red fruits, and drinks, such as red wine. This compound has shown great antioxidant capacity due to its chemical structure. In this study, we evaluated the effect of chronic RSVL treatment on oxidative stress and cell loss in the prefrontal cortex, hippocampus, and cerebellum of 20‐month‐old rats, as well as its impact on recognition memory and motor behavior. Rats treated with RSVL showed an improvement in locomotor activity and in short‐ and long‐term recognition memory. Likewise, the concentration of reactive oxygen species and lipid peroxidation decreased significantly in the group with RSVL, coupled with an improvement in the activity of the antioxidant system. Finally, with the help of hematoxylin and eosin staining, it was shown that chronic treatment with RSVL prevented cell loss in the brain regions studied. Our results demonstrate the antioxidant and neuroprotective capacity of RSVL when administered chronically. This strengthens the proposal that RSVL could be an important pharmacological option to reduce the incidence of neurodegenerative diseases that affect older adults.
Gallic acid improves recognition memory and decreases oxidative‐inflammatory damage in the rat hippocampus with metabolic syndrome
Metabolic syndrome (MS) results from excessive consumption of high‐calorie foods and sedentary lifestyles. Clinically, insulin resistance, abdominal obesity, hyperglycemia, dyslipidemia, and hypertension are observed. MS has been considered a risk factor in the development of dementia. In the brain, a metabolically impaired environment generates oxidative stress and excessive production of pro‐inflammatory cytokines that deteriorate the morphology and neuronal function in the hippocampus, leading to cognitive impairment. Therapeutic alternatives suggest that phenolic compounds can be part of the treatment for neuropathies and metabolic diseases. In recent years, the use of Gallic Acid (GA) has demonstrated antioxidant and anti‐inflammatory effects that contribute to neuroprotection and memory improvement in animal models. However, the effect of GA on hippocampal neurodegeneration and memory impairment under MS conditions is still unclear. In this work, we administered GA (20 mg/kg) for 60 days to rats with MS. The results show that GA treatment improved zoometric and biochemical parameters, as well as the recognition memory, in animals with MS. Additionally, GA administration increased hippocampal dendritic spines and decreased oxidative stress and inflammation. Our results show that GA treatment improves metabolism: reducing the oxidative and inflammatory environment that facilitates the recovery of the neuronal morphology in the hippocampus of rats with MS. Consequently, the recognition of objects by these animals, suggesting that GA could be used therapeutically in metabolic disorders that cause dementia.
Gallic acid improves recognition memory and decreases oxidative‐inflammatory damage in the rat hippocampus with metabolic syndrome
Metabolic syndrome (MS) results from excessive consumption of high‐calorie foods and sedentary lifestyles. Clinically, insulin resistance, abdominal obesity, hyperglycemia, dyslipidemia, and hypertension are observed. MS has been considered a risk factor in the development of dementia. In the brain, a metabolically impaired environment generates oxidative stress and excessive production of pro‐inflammatory cytokines that deteriorate the morphology and neuronal function in the hippocampus, leading to cognitive impairment. Therapeutic alternatives suggest that phenolic compounds can be part of the treatment for neuropathies and metabolic diseases. In recent years, the use of Gallic Acid (GA) has demonstrated antioxidant and anti‐inflammatory effects that contribute to neuroprotection and memory improvement in animal models. However, the effect of GA on hippocampal neurodegeneration and memory impairment under MS conditions is still unclear. In this work, we administered GA (20 mg/kg) for 60 days to rats with MS. The results show that GA treatment improved zoometric and biochemical parameters, as well as the recognition memory, in animals with MS. Additionally, GA administration increased hippocampal dendritic spines and decreased oxidative stress and inflammation. Our results show that GA treatment improves metabolism: reducing the oxidative and inflammatory environment that facilitates the recovery of the neuronal morphology in the hippocampus of rats with MS. Consequently, the recognition of objects by these animals, suggesting that GA could be used therapeutically in metabolic disorders that cause dementia.